Masteron cycle was generally well tolerated. Side effects are mostly mild and transient in nature.
According to the World Health Organization adverse reactions are classified according to their rate of development as follows: very common and very rare ; the frequency is unknown – according to available data to set the frequency of occurrence was not possible. Disorders of the nervous systemUncommon: headache. Disorders of the gastrointestinal tract often: change feces color (due to the breeding not grown deep iron, has no clinical significance), often : diarrhea, nausea, dyspepsia; very rare:abdominal pain, constipation, vomiting, discoloration of tooth enamel. Violations of the skin and subcutaneous tissue disorders very rare: urticaria, rash, itchy skin. If any of these instructions side effects compounded, or if you notice any other side effects not mentioned in the instructions – inform your doctor.
Interaction with other drugs
The preparation includes the complex-bound iron, which leads to a low probability of ionic interactions with food components (oxalates, tannins, etc.), a well as other drugs (eg., Tetracyclines, antacids).
Interaction with other drugs funds or food have been identified.
The simultaneous use of parenteral iron preparations and other oral preparations of iron (III) hydroxide polimaltozata not recommended due to the pronounced inhibition of absorption of iron supplied orally.
In cases of anemia caused by infectious or malignant disease, iron accumulates in the reticuloendothelial system from which mobilized and utilized only after the treatment of the underlying disease.
In applying chair is painted in a dark color that does not have any clinical significance . The has no influence on the test results for occult blood (hemoglobin selectively against); therefore, suspend iron therapy is not required.
Note for patients with diabetes: 1 chewable tablet masteron cycle contains.
Note for patients with phenylketonuria: the contains aspartame , which is phenylalanine source, in an amount equivalent to 1.5 mg per tablet.
Effects on ability to drive vehicles, machinery
Masteron cyclenot affect the ability to drive a car and mechanisms that require high concentration of attention management.
Chewable Tablets 100 mg. Primary Packaging 10 tablets placed blister. Secondary packaging On 3, 5 or 9 strips or blisters are placed in a cardboard box with the instructions for medical use.